New ADHD Medication SIMTRIYO: What Women Need to Know

If you or your child has ADHD, you’ve probably tried stimulants like Adderall or non-stimulants like Strattera—and maybe neither was quite right. A new ADHD medication called SIMTRIYO (centanafadine) just received FDA approval. It works differently from anything available before. Here’s what women managing ADHD need to know about this new ADHD medication, including how it compares to existing treatments, what the research shows, and what questions to ask your doctor.

A new ADHD medication with a novel mechanism

Here’s the thing: most ADHD meds focus on one or two brain chemicals. Stimulants like Adderall boost norepinephrine and dopamine. Non-stimulants like Strattera mainly affect norepinephrine. But SIMTRIYO is the first to add serotonin into the mix. That matters because serotonin affects your mood, emotions, and impulse control—areas where many women with ADHD struggle.

According to the Otsuka FDA approval announcement, this new ADHD medication (called an NDSRI) offers “a new treatment approach” for the condition. “I think it will help, especially for patients who have tried other medications without much success,” said Dr. Daniel Ganjian, a pediatrician at Providence Saint John’s Health Center. “It’s adding more tools to our arsenal.”

How does this new ADHD medication compare to others?

Let’s be honest: you want to know how SIMTRIYO stacks up against Adderall, Vyvanse, Ritalin, and Strattera. No head-to-head trials exist yet, but researchers did careful indirect comparisons. An indirect comparison study in the Journal of Managed Care & Specialty Pharmacy matched data from centanafadine trials against published data for other meds. Here’s what they found:

Bottom line: this new ADHD medication is not more effective than the strongest stimulants, but it offers a gentler ride. For women who have struggled with side effects or have mild-to-moderate ADHD, it could be a game-changer.

What the research shows: Clinical trial results

The FDA approval rests on four phase 3 trials with over 1,400 people across all age groups. The results were clear: those taking SIMTRIYO showed much greater improvement in ADHD symptoms compared to a placebo. A phase 3 trial in teens published in JAACAP found that the higher dose (328.8 mg) produced a clear drop in ADHD rating scores by week six—with results separating from placebo as early as week one.

One thing stands out: SIMTRIYO also helps with planning, organization, and starting tasks. A study in the Journal of Child and Adolescent Psychopharmacology found that children taking centanafadine had a 50% higher chance of meaningful improvement in focus and planning compared to placebo. For teens, that number jumped to 88%. They also saw big gains in learning. For women managing their own ADHD or their child’s, these real-world benefits matter.

The benefits appear to last. A 52-week open-label safety study followed 662 adults (51% of them women) and found that ADHD scores improved up to 57% from the start. No drug-related serious side effects were reported.

Safety and side effects: What you need to know

No medication is perfect. And this new ADHD medication comes with important safety warnings. According to the FDA prescribing information, the drug carries a boxed warning—the strongest type—for two things:

• Suicidal thoughts and actions in children ages 6 to 12. Families should watch closely for mood changes.
• Risk of abuse, misuse, and addiction. SIMTRIYO will be a controlled substance once DEA scheduling is done.

Common side effects differ by age. In children: less appetite, nausea, rash, headache, and belly pain. In adults: headache, less appetite, trouble sleeping, dry mouth, nausea, and diarrhea. About 12% of adults in the long-term study stopped due to side effects.

Important drug interactions: Because SIMTRIYO affects serotonin, taking it with antidepressants (SSRIs, SNRIs), triptans, St. John’s wort, or opioids raises the risk of serotonin syndrome—a rare but serious condition. Always tell your doctor about every med and supplement you take.

Other cautions: SIMTRIYO can raise blood pressure and heart rate. It may cause cold fingers or toes (Raynaud’s phenomenon) and worsen tics. It’s not advised during pregnancy unless clearly needed. A pregnancy registry is available at 866-961-2388.

What this new ADHD medication means for women

Now, you may be thinking: “That’s interesting, but what does it mean for me?” Here’s where TEOHL’s view adds something you won’t find elsewhere.

ADHD looks different in women. Many of us are diagnosed later in life—often in our 30s or 40s—because our signs are more internal: brain fog, mood swings, trouble keeping life organized. We are also more likely to have anxiety or depression. That is exactly where SIMTRIYO’s triple mechanism could help. The serotonin boost may ease the mood ups and downs that so many women with ADHD describe.

Otsuka conducted a phase 3b study in adults with ADHD plus anxiety. It showed a clear improvement in ADHD symptoms (not necessarily anxiety symptoms) among adults with ADHD who also had anxiety, compared to placebo. While SIMTRIYO is not FDA-approved for anxiety, the data hints it could be a smart pick for women who need both conditions addressed.

What about hormones? The research on SIMTRIYO did not look at menstrual cycles or perimenopause. But we know that estrogen and progesterone affect dopamine and serotonin. If you have noticed your ADHD signs worsen at certain points in your cycle, it is worth talking with your doctor about how this new ADHD medication may work with your body’s patterns.

Questions to ask your doctor about SIMTRIYO

Ready to bring this up with your provider? Here is a conversation guide for your next visit:

• Could SIMTRIYO work well for me given my current symptoms and other meds?
• How do its side effects compare to what I have had on other meds? (Especially if appetite loss or insomnia has been a problem.)
• Would the serotonin effect help my mood or anxiety, or should I stay on a separate antidepressant?
• What is the right dose for me? (Your doctor will decide the best starting dose based on your age, weight, and needs. The available capsule sizes are 140 mg, 210 mg, and 280 mg.)
• How should I take it? (Once daily in the morning, with or without food. Per the FDA label, if you cannot swallow the capsule, you can open it and sprinkle the contents on one spoonful of applesauce, yogurt, or orange juice. Swallow right away, do not chew.)
• What about alcohol? (The FDA label advises avoiding alcohol for at least 2 hours after your dose, since alcohol can cause the medicine to release too fast.)
• What should I watch for in terms of side effects, especially mood changes?
• Will my insurance cover it, and what is the expected cost? (New brand-name meds are often pricey at first.)

The Bottom Line

SIMTRIYO is a truly new option in the ADHD medication world—not just another stimulant or non-stimulant, but a whole new class that works on three brain chemicals instead of one or two. For women who have had side effects from older treatments, or who have both ADHD and mood issues, it is worth exploring with your doctor.

That said, medication is only one piece of the puzzle. As Dr. Max Wiznitzer, professor of pediatrics and neurology at Case Western Reserve University, put it: “Medication can get you to the starting line, but you still have to run the race.” The race includes therapy, planning skills, good sleep, regular exercise, and a support network.

Talk with your healthcare provider about what is right for you. And remember: you are not alone. New options mean new possibilities.